Pirenzepine

"Tabe" redirects here. For the assessment tests called TABE, see Tests of Adult Basic Education.

Pirenzepine

221px
Systematic (IUPAC) name
11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one
Clinical data
AHFS/Drugs.com	monograph
Identifiers
CAS Number	28797-61-7 Y
ATC code	A02BX03 (WHO)
PubChem	CID: 4848
IUPHAR/BPS	328
DrugBank	DB00670 Y
ChemSpider	4682 Y
UNII	3G0285N20N Y
KEGG	D08389 Y
ChEBI	CHEBI:8247 Y
ChEMBL	CHEMBL9967 Y
Chemical data
Formula	C19H21N5O2
Molecular mass	351.403 g/mol
SMILES O=C3c1ccccc1N(C(=O)CN2CCN(C)CC2)c4ncccc4N3
InChI InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26) Y Key:RMHMFHUVIITRHF-UHFFFAOYSA-N Y
(verify)

Pirenzepine (Gastrozepin), an M1 selective antagonist, is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), the result being an increase in gastric motility and digestion. It has no effects on the brain and spinal cord as it cannot diffuse through the blood–brain barrier.

Pirenzepine has been investigated for use in myopia control.

See also

• AFDX-384